国产日韩欧美色图,国产无码国产精品视频 ,av不卡在线观看一区

The Phase II/III Clinical Trial of Deuremidevir Hydrobromide (VV116) Dry Suspension for the Treatment of Respiratory Syncytial Virus Infection in Infants and Children Officially Launched

june — Fri, 15 Nov 2024 06:26:13 +0000

From January 29 to 30, 2024, a “randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the safety and efficacy of Deuremidevir Hydrobromide dry suspension in hospitalized infants and children with Respiratory Syncytial Virus infection” was successfully initiated at Shulan (Hangzhou) Hospital, Linfen Central Hospital, and Mianyang Central Hospital. This signifies that Deuremidevir Hydrobromide (V116) dry […]

The post The Phase II/III Clinical Trial of Deuremidevir Hydrobromide (VV116) Dry Suspension for the Treatment of Respiratory Syncytial Virus Infection in Infants and Children Officially Launched appeared first on Vigonvita Life Sciences Co., Ltd..

ONVITA? (TPN171), an Innovative Drug for the Treatment of Erectile Dysfunction (ED), Debuts at the 24th World Meeting on Sexual Medicine

june — Fri, 15 Nov 2024 06:23:34 +0000

From December 15 to 17, 2023, the ‘24th World Meeting on Sexual Medicine’ hosted by the International Society for Sexual Medicine (ISSM) was held in Dubai, UAE. This conference brought together more than 500 sexual medicine experts and scholars from over 100 countries and regions around the world to discuss the latest research achievements and […]

The post ONVITA? (TPN171), an Innovative Drug for the Treatment of Erectile Dysfunction (ED), Debuts at the 24th World Meeting on Sexual Medicine appeared first on Vigonvita Life Sciences Co., Ltd..

Clinical research results of the domestic COVID-19 oral drug Mindvy? were published in the authoritative international medical journal The Lancet – Infectious Diseases.

june — Fri, 15 Nov 2024 06:18:36 +0000

November 23, 2023, Beijing time The results of a phase Ⅲ clinical study of the domestic COVID-19 oral drug Mindvy? (Deuremidevir hydrobromide tablets, product code: VV116/JT001) co-developed by Vigonvita, were published on the authoritative periodical in the field of infectious diseases , The Lancet Infectious Diseases (IF: 56.3); previously the results of the “head-to-head” phase […]

The post Clinical research results of the domestic COVID-19 oral drug Mindvy? were published in the authoritative international medical journal The Lancet – Infectious Diseases. appeared first on Vigonvita Life Sciences Co., Ltd..

Phase IIa clinical trial results of TPN171H tablets for the treatment of pulmonary arterial hypertension announce at the United States AHA 2023 Conference

june — Fri, 15 Nov 2024 06:16:07 +0000

On the morning of November 12, 2023 Eastern Time, USA, the results of the Phase IIa clinical trial (ClinicalTrials. gov ID: NCT04483115) of TPN171H tablets for the treatment of pulmonary arterial hypertension were announced at the 2023 (AHA Scientific Sessions) Featured Science. This is a clinical study jointly led by Professor Yong Huo of Peking […]

The post Phase IIa clinical trial results of TPN171H tablets for the treatment of pulmonary arterial hypertension announce at the United States AHA 2023 Conference appeared first on Vigonvita Life Sciences Co., Ltd..

The expert discussion meeting on phase II/III clinical trial protocols for Deuremidevir Hydrobromide (VV116) dry suspension for the treatment of Respiratory Syncytial Virus infection in infants and young children was successfully held

june — Fri, 15 Nov 2024 06:12:06 +0000

On November 2, 2023, an expert discussion meeting on the Phase II/III clinical trial protocol for the treatment of respiratory syncytial virus (RSV) infection in infants and young children with deuremidevir hydrobromide (VV116) was successfully held at Shulan (Hangzhou) Hospital, adopting a combination of online and offline.